Source link : https://www.newshealth.biz/health-news/subcutaneous-amivantamab-plus-lazertinib-non-inferior-to-iv-dosing-in-nsclc/
CHICAGO — Subcutaneous amivantamab (Rybrevant) was non-inferior to IV amivantamab for pre-treated patients with refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC), with the suggestion of a possible survival benefit, according to the phase III PALOMA-3 trial. The 418 patients in the study had disease progression after treatment with osimertinib (Tagrisso) and chemotherapy. Amivantamab was […]
Author : News Health
Publish date : 2024-06-01 22:02:42
Copyright for syndicated content belongs to the linked Source.
Categories